Biologics

FDA Analysis Finds CMC Issues Dominate AAV Gene Therapy Reviews

Chemistry, manufacturing and controls (CMC) concerns accounted for 58% of the topics raised in FDA information requests during reviews of seven adeno-associated virus (AAV) gene therapy applications, according to an analysis by agency scientists published 11/6 in Nature Reviews Drug Discovery.

The analysis, conducted by CBER researchers, examined 278 information request communications covering 662 individual topics across seven BLAs. The agency approved eight AAV-based gene therapies between 2017 and 2025.

Clinical questions accounted for 13% of the topics, followed by bioanalytical issues, including clinical pharmacology (11%), devices and companion diagnostics (7%), regulatory affairs (6%), and pharmacology/toxicology (3%).

The researchers identified analytical assay development and validation, product characterization, manufacturing consistency and potency testing as recurring regulatory challenges.

They also found that nearly all seven approvals involved multiple postmarketing commitments (PMCs), with a median of six per product. Most of these concerned CMC issues, including analytical method qualification, potency assay development and validation, and revisions to product acceptance criteria.

Median timelines for fulfilling the commitments ranged from approximately two to four years.

Applications generating more preapproval information requests tended to require longer postmarketing commitment timelines, suggesting that unresolved analytical questions frequently extended beyond licensure. Conversely, products with established manufacturing processes and well-defined analytical systems achieved faster closure.

The analysis also found that six of the eight approved AAV products incorporated diagnostic assays or specialized delivery devices requiring regulatory coordination beyond the BLA review. The authors recommended earlier development of companion diagnostics and closer coordination among manufacturing, clinical and quality teams.

Although postmarketing requirements were relatively uncommon, the researchers said their use reflected FDA's willingness to accept some residual uncertainty when the benefit-risk balance supported approval.

The average number of FDA information request communications per application declined between the earliest and most recent approvals, particularly for CMC topics. The authors suggested that improved applicant readiness and consolidation of questions into fewer requests may have contributed.

They concluded that sponsors could reduce regulatory uncertainty by addressing analytical methods, potency assays, manufacturing controls and diagnostic requirements earlier in development.

Researchers Identify Opportunities, Limits for Animal Testing Alternatives

As FDA moves to reduce animal testing requirements for certain drugs, researchers say emerging technologies involving human organoids, organ-on-a-chip systems and artificial intelligence could replace some traditional animal studies, although significant scientific and regulatory limitations remain. In a Perspective published 11/2 in The Innovation, researchers from

Democratic Congress Could Complicate User Fee Reauthorization

FDA officials remain confident that Congress will reauthorize the agency's four major user fee programs before they expire next September, although Democratic control of Congress and the prospect of Sen. Bernie Sanders (I-VT) chairing the Senate HELP Committee could complicate the reauthorization over the already-negotiated agreements.

Merck's Efinopegdutide Shows MASH Resolution, Fibrosis Improvement

Merck's investigational GLP-1/glucagon receptor dual agonist efinopegdutide (MK-6024) demonstrated higher rates of MASH resolution and liver fibrosis improvement than placebo in a Phase 2b trial involving patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced fibrosis. The results, presented at the American Association

FDA Clarifies Drug Interaction Study Requirements, Labeling Expectations

FDA officials say drug manufacturers may be able to establish dosing recommendations and characterize drug-drug interaction risks without conducting additional clinical studies, including through pharmacokinetic modeling and real-world data, provided the evidence is scientifically justified. During a series of FDA presentations released 11/4 on [Drug Interaction Information

Read more

Researchers Identify Opportunities, Limits for Animal Testing Alternatives

Democratic Congress Could Complicate User Fee Reauthorization

Merck's Efinopegdutide Shows MASH Resolution, Fibrosis Improvement

FDA Clarifies Drug Interaction Study Requirements, Labeling Expectations